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Abstract The presence and tissue localization of macrophage 
migration inhibitory factor (MIF) in human skin were examined. 
Reverse transcription-polymerasc chain reaction analysis re- 
vealed that MIF mRNA was expressed in both surgically 
obtained normal human epidermis and primary cultured human 
keratinocytes. The expression of MIF was further conf'wmed by 
Western blot analysis, which demonstrated a single band at about 
12.5 kDa using a polyelonal antibody against human recombi- 
nant MIF. Immunohistochemical studies showed that MIF 
existed in human epidermis, especially in the basal layer. The 
pathophysiological role of MIF in human skin remains 
undefined; however, the present results indicate that MIF may 
play an important role in immunity, inflammation and cellular 
differentiation of epidermal cells. 
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1. Introduction 
epidermal keratinocytes a revealed by reverse transcription- 
polymerase chain reaction (RT-PCR) and Western blot anal- 
yses. Furthermore, we demonstrate he intracellular localiza- 
tion of MIF in human epidermis by immunohistochemistry. 
These novel findings suggest additional pathophysiological 
functions for MIF in cutaneous immunity, inflammation, 
and cellular differentiation. 
2. Materials and methods 
2.1. Materials" 
The following materials were obtained from commercial sources. 
Nitrocellulose membrane filters from Millipore (Bedford, MA, 
USA); Isogen RNA extraction kit from Nippon Gene (Tokyo, Ja- 
pan); M-MLV reverse transcriptase from Gibco (Grand Island, NY, 
USA); Taq DNA polymerase from Perkin-Elmer (Norwalk, CO, 
USA); horseradish peroxidase-conjugated goatanti-rabbit antibody 
from Pierce (Rockford, IL, USA); Vector ABC Kit from Vector La- 
boratories (Burlingame, CA, USA); FITC from Pierce (Rockford, IL, 
USA); Konica immunostaining kit from Konica (Tokyo, Japan); 
Tissue-Tek O.C.T. Compound from Miles Scientific (Naperville, IL, 
USA) and Protein A Sepharose from Pharmacia (Uppsala, Sweden). 
All other chemicals were of reagent grade. 
The skin is an important barrier that protects the body 
against damage from the outside environment. It has been 
reported that various cytokines play important roles in 
homeostasis of normal skin and in its pathology [1]. Diverse 
stimuli trigger a cutaneous inflammatory esponse by activat- 
ing specific pro-inflammatory cytokines, such as tumor necro- 
sis factor-~ (TNF-c0 and interleukin-1 (IL-1); however, the 
detailed interrelation of the cytokines to the pathophysiologi- 
cal mechanism has not been well elucidated. 
Macrophage migration inhibitory factor (MIF) was the first 
lymphokine reported in the guinea pig to prevent he migra- 
tion of macrophages out of capillary tubes [2]. Human MIF 
cDNA was first cloned from human T-lymphocytes, and it 
was revealed that MIF consists of 114 amino acid residues 
[3]. MIF has long been considered to be expressed exclusively 
in activated T-lymphocytes; however, a recent report indi- 
cated that macrophages are another major source of MIF 
[4]. We cloned rat MIF cDNA, and reported its physicochem- 
ical properties [5,6]. Moreover, we succeeded in the crystal- 
lization of both human and rat MIF [7,8], During the course 
of our MIF study, we unexpectedly found the presence of 
MIF in human corneal epithelium (manuscript submitted 
for publication). This finding indicated that MIF might not 
be exclusively expressed in T-lymphocytes and monocytes/ 
macrophages. 
In the present study, we investigated the presence of MIF in 
human skin. Here we report the expression of MIF in human 
*Corresponding author. Fax: (81) (11) 706 7864. 
2.2. Preparation of rabbit polyclonal antibodies against human MIF 
Polyclonal anti-human MIF serum was generated by immunizing 
New Zealand White rabbits with purified recombinant human MIF. 
Human recombinant MIF was expressed in E. coli and purified to 
homogeneity aspreviously described [6]. In brief, the rabbits were 
inoculated intradermally with 100 gg of MIF diluted in complete 
Freund adjuvant at weeks l and 2, and with 50 gg of MIF diluted 
in incomplete Freund adjuvant at week 4. Immune serum was col- 
lected 1 week after the last inoculation. The IgG fraction was pre- 
pared using Protein A Sepharose according to the manufacturer's 
protocol. 
2.3. Cell culture 
The primary cultured normal human keratinocytes (second passage) 
were obtained from Kurabou Co. (Osaka, Japan). The cultures were 
fed on glass coverslips ina medium of consisting serum-free modified 
MCDB 153, supplemented with hydrocortisone (0.5 Ixg/ml), insulin (5 
gg/ml), epidermal growth factor (10 ng/ml), bovine pituitary extracts 
(150 gg/ml), and calcium (0.15 mM), The keratinocytes were grown in 
a humidified atmosphere under 5% CO2 at 37°C. For the analyses of 
RT-PCR, Western blot and immunofluorescence microscopy, tertiary 
cultures of these cells were harvested before the colonies became con- 
fluent. 
2.4. RT-PCR analysis 
Human epidermis was surgically obtained from a normal subject, 
and was frozen immediately in liquid nitrogen until use. The epider- 
mis was separated from the dermis by fine forceps. The total RNA 
was extracted from the epidermis or primary cultured keratinocytes 
with an lsogen RNA extraction kit. The reverse transcription ofRNA 
was carried out by M-MLV reverse transcriptase using oligo-dT pri- 
mer and subsequent amplification using Taq DNA polymerase. PCR 
was carried out for forty cycles of denaturation at 94°C for 1 rain, 
annealing at 53°C for 2 min and extension at 72°C for 1 min using a 
thermal cycler (Perkin-Elmer, Model 2400). MIF primers used were 
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Fig. 1. RT-PCR analysis of MIF mRNA. RT-PCR was carried out 
as described in Materials and Methods. The PCR products were 
electrophoresed on 2% agarose gel. Lane 1, human epidermis; lane 
2, primary cultured keratinocytes; lane 3, the molecular size marker 
(pBR322 DNA/Alul). The RT-PCR product of ~-actin is shown at 
the bottom of each lane. 
5'-CTCTCCGAGCTCACCCAGCAG-3' (58-78) (forward) and 5'- 
CGCGTTCATGTCGTAATAGTT-3' (292-312) (reverse). I~-Actin 
primers used were 5'-CGTTCTGGCGGCACCACCAT-Y (936-935) 
(forward) and 5'-GCAACTAAGTCATAGTCCGC-3' (1170-1189) 
(reverse). After PCR, the amplified products were analyzed by agarose 
gel electrophoresis. 
2.5. Western blot analysis 
The tissue samples of homogenates of normal epidermis or the 
primary cultured keratinocytes were treated with 4 volumes of SDS- 
reducing buffer (60 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 5% 
~-mercaptoethanol, and0.025% Bromophenol b ue), and subjected to 
SDS-PAGE as described [9]. Proteins on the gel were transferred 
electrophoretically to a nitrocellulose membrane by the procedure of 
Towbin et al. In brief, the membrane was intensively washed with 
phosphate-buffered saline (PBS), and incubated with the polyclonal 
anti-human MIF antibody at room temperature for 1 h. After wash- 
ing with PBS, the membrane was incubated with peroxidase-conju- 
gated goat antibodies against rabbit IgG at room temperature for 1 h. 
After the reaction, proteins were visualized with a Konica immuno- 
staining kit as recommended in the manufacturer's protocol. 
2.6. Immunohistochernistry 
Biopsy samples from normal human skin were immediately em- 
bedded in Tissue-Tek O.C.T. Compound, snap frozen in liquid nitro- 
gen and stored at -80°C until further processing. The frozen em- 
bedded tissues were cut into 4-gm sections which were then fixed in 
acetone for 10 rnin at room temperature. They were stained with an 
avidin-biotin peroxidase complex procedure using a Vector ABC Kit 
according to the manufacturer's protocol. In brief, the sections were 
incubated overnight at 4°C with the anti-human MIF antibody. After 
three washes with PBS, the samples were reacted with biotinylated 
goat anti-rabbit lgG and avidin-biotin complex at room temperature 
for 30 min. The reaction was developed in 3,3'-diaminobenzidine tet- 
rahydrochloride containing hydrogen peroxide (0.01%), and the tissue 
samples were mounted with alkylacrylates. 
Immunohistochemical study of the primary cultured human kerati- 
nocytes was also carried out using a fluorescence-conjugated s cond- 
ary antibody. The tertiary cultures of cells grown on cover slips were 
rinsed with PBS and dipped in -20°C acetone for 5 min. The fixed 
cells were incubated with the anti-human MIF antibody at 37°C for 
1 h, followed by FITC-labeled goat anti-rabbit IgG (secondary anti- 
body) at 37°C for 30 min. A fluorescence microscope (Nikon, Tokyo, 
Japan) was used for immunohistochemical observation. 
3. Results 
3.1. RT -PCR 
MIF mRNA expression in the human epidermis and the 
primary cultured keratinocytes was examined by RT-PCR 
analysis. At the expected molecular size (255 bp), MIF  RT- 
PCR products on the human epidermis and the cultured ker- 
atinocytes were observed in agarose gel (Fig. 1). They ex- 
pressed MIF to similar extents assumed from the similar in- 
tensities of their PCR products normalized by the intensities 
of [~-actin. 
3.2. Western blot analysis 
To further confirm the presence of MIF in the human epi- 
dermis, Western blot analysis was performed using the anti- 
body against human M1F. The immunoblot analysis revealed 
that the normal human epidermis and the primary cultured 
keratinocytes could produce MIF  that migrated to the corre- 
sponding molecular weight, about 12.5 kDa, visualized by a 
Konica immunostaining kit (Fig. 2). Pre-immune rabbit IgG 
did not react with human MIF in the immunoblot analysis 
(data not shown). This result indicated that MIF  was bio- 
synthesized in the human epidermis. 
3.3. lmmunohistochemisry 
The epidermis obtained from a normal subject was posi- 
tively stained by the antibody against human MIF in the 
cytoplasm, especially in the basal layer (Fig. 3a,b). The posi- 
tive staining regions appearing in the middle and the left side 
of the spinous cell layers were considered to be keratinocytes 
of the epidermal basal cells. Their appearance was technically 
caused by the direction of the section. Some small positive 
staining spots were also observed in the dermis. These were 
considered to be endothelial cells of small blood vessels. 
Furthermore, ccrine sweat ductal cells and myoepithelial cells 
of eccrine sweat glands were also stained (data not shown). 
The positive staining was not observed when the tissue sample 
was stained with pre-immune rabbit IgG (Fig. 3c). To confirm 
that MIF localized in the cytoplasm of epidermal keratino- 
cytes, we further examined the localization of MIF in cultured 
human keratinocytes using an FITC-labeled secondary anti- 
body. It clearly demonstrated that the cytoplasm of cultured 
keratinocytes was positively stained (Fig. 3d). No specific po- 
sitive staining was observed when the tissue was reacted with 
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Fig, 2. Western blot analysis of the human epidermis for MIF. The 
tissue samples were collected, electrophoresed, transferred to a nitro- 
cellulose membrane, and visualized by a Konica immunostaining kit 
as described in section 2. Lane l, recombinant human MIF (200 
gg); lane 2, recombinant human MIF (50 gg); lane 3, human epi- 
dermis (50 gg of protein); lane 4, primary cultured keratinocytes 
(5 × 105 cells); lane 5, prestained molecular marker (Biolabs). 
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Fig. 3. Immunohistochemistry of MIF in normal human skin. a, a tissue specimen obtained from normal skin was stained using a Vector ABC 
immunostaining kit reacted with anti-human MIF antibody (x 50). b, high-magnification f Fig. 3a (× 200). c, a control tissue specimen reacted 
with pre-immune rabbit IgG (x 50). d, primary cultured keratinocytes were reacted with anti-human MIF antibody followed by an FITC-la- 
beled secondary antibody (x 100). 
pre-immune FITC-labeled rabbit IgG or with anti-human 
MIF IgG pretreated with an excess amount of recombinant 
MIF (data not shown). 
4. Discussion 
In the present study, we have demonstrated the expression 
of MIF in human epidermis by RT-PCR and Western blot 
analyses. Moreover, the presence of MIF was confirmed by 
immunohistochemistry which showed that MIF was distribu- 
ted mainly in the cytoplasm in the keratinocytes. The unex- 
pected tissue localization of the pro-inflammatory c tokine in 
tissue other than T-lymphocytes and monocytes/macrophages 
should help further understanding of the immunological reac- 
tion in human skin. 
To date, several cytokines, including IL-10t, TNF-c4 IL-6, 
IL-8, granulocyte-macrophage colony-stimulating factor 
(GM-CSF), and transforming growth factor-t~ (TGF-ct), 
have been found in epidermal keratinocytes [1]; however, 
only IL-lc~ could be shown to be stored in normal skin in a 
biologically active form [10]. Cytokines released from kerati- 
nocytes can be induced by environmental stimuli such as trau- 
ma, bacterial toxins and ultraviolet light. For example, IL-1 
and TNF-ct release from keratinocytes are induced by ultra- 
violet radiation [11,12], and physical damage to keratinocytes 
can stimulate IL-1 release [13]. In addition, IL-1 in concert 
with other cytokines such as GM-CSF, IL-6, and TGF-t~, 
stimulates keratinocyte proliferation [14,15]. That is, it is 
very likely that cytokines are a vital element of the patholo- 
gical mechanism in inflammatory skin diseases. 
The roles of MIF in regulating macrophages have been 
investigated in various tissues. MIF, originally identified as 
a lymphokine concentrating macrophages at inflammatory 
sites, is a potent activator of macrophages [16]. MIF has 
been considered to be exclusively expressed in activated T- 
lymphocytes and macrophages, and responses to stimuli 
such as wounds and infection [4,17]. In this study, we de- 
scribed the presence of MIF in human epidermal keratino- 
cytes for the first time. However, the pathophysiological func- 
tion of MIF in the human skin still remains undefined. 
Recently, Wistow et al. reported that MIF mRNA expression 
was correlated with cell differentiation of lens cells [18]. This 
finding suggests the possibility that MIF produced uring the 
immune reaction and inflammatory processes may cause epi- 
dermal hyperplasia since skin epidermal hyperplasia nd in- 
flammation are considered to be linked to bioactions of loca- 
lized cytokines and growth factors [14]. This possibility is 
supported by the fact that the basal cells of the epidermis 
are highly proliferative in nature. 
In conclusion, the present results suggest hat MIF is im- 
portant in the cytokine network involved in human skin 
pathogenesis. Lately, MIF was found to be a glucocorticoid- 
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induced modulator of cytokine production [19]. This indicates 
that M IF  is a critical component of the immune system and 
acts together with glucocorticoids to regulate immunity and 
inflammation. Considering this observation together with our 
present results, it is speculated that M IF  may play an impor- 
tant role in cutaneous immunity and the inflammatory process 
in addition to its role in epidermal cell proliferation and dif- 
ferentiation. Experiments to test this possibility are currently 
underway. 
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